Old	New	Differences
1	1
2	2
3	3
4	4	Req. No. 2393 Page 1 1
5	5	2
6	6	3
7	7	4
8	8	5
9	9	6
10	10	7
11	11	8
12	12	9
13	13	10
14	14	11
15	15	12
16	16	13
17	17	14
18	18	15
19	19	16
20	20	17
21	21	18
22	22	19
23	23	20
24	24	21
25	25	22
26	26	23
27	27	24
28	28	1
29	29	2
30	30	3
31	31	4
32	32	5
33	33	6
34	34	7
35	35	8
36	36	9
37	37	10
38	38	11
39	39	12
40	40	13
41	41	14
42	42	15
43	43	16
44	44	17
45	45	18
46	46	19
47	47	20
48	48	21
49	49	22
50	50	23
51	51	24
52	52
53	53	STATE OF OKLAHOMA
54	54
55	55	2nd Session of the 58th Legislature (2022)
56	56
57	57	SENATE BILL 1438 By: Allen
58	58
59	59
60	60
61	61
62	62
63	63	AS INTRODUCED
64	64
65	65	An Act relating to substance abuse services; amending
66	66	43A O.S. 2021, Section 3 -601, which relates to opioid
67	67	substitution treatment progra ms; prohibiting sale or
68	68	dispensing of methadone for unsupervised use; and
69	69	providing an effective date .
70	70
71	71
72	72
73	73
74	74
75	75	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
76	76	SECTION 1. AMENDATORY 43A O.S. 2021, Section 3-601, is
77	77	amended to read as follows:
78	78	Section 3-601. A. Any Class II controlled dangerous substance,
79	79	when used in this state by an opioid substitu tion treatment program
80	80	for persons with a history of opioid addiction to or physiologic
81	81	dependence on controlled dangerous substances, shall only be used:
82	82	1. In treating pers ons with a history of addiction ;
83	83	2. In treating persons with a one -year history of opioid
84	84	addiction to or physiologic dependence on controlled dangerous
85	85	substances, as defined by the Code of Federal Regu lations, and
86	86	documentation of attempting another type of treatment; or
87	87
88	88
89	89	Req. No. 2393 Page 2 1
90	90	2
91	91	3
92	92	4
93	93	5
94	94	6
95	95	7
96	96	8
97	97	9
98	98	10
99	99	11
100	100	12
101	101	13
102	102	14
103	103	15
104	104	16
105	105	17
106	106	18
107	107	19
108	108	20
109	109	21
110	110	22
111	111	23
112	112	24
113	113	1
114	114	2
115	115	3
116	116	4
117	117	5
118	118	6
119	119	7
120	120	8
121	121	9
122	122	10
123	123	11
124	124	12
125	125	13
126	126	14
127	127	15
128	128	16
129	129	17
130	130	18
131	131	19
132	132	20
133	133	21
134	134	22
135	135	23
136	136	24
137	137
138	138	3. If clinically appropriate, the program physician may waive
139	139	the requirement of a one -year history of opioid addiction for
140	140	consumers within six (6) months of release from a penal inst itution,
141	141	for consumers with a pregnancy verified by the program physician, or
142	142	for consumers having previously received treatment for opioid
143	143	addiction and within two (2) years of discharge from that treatmen t
144	144	episode.
145	145	B. Any conviction for a violation of t he provisions of this
146	146	section or any rules promulgated pursuant to the provisions of this
147	147	section shall be a felony.
148	148	C. For the purposes of this section, "opioid substitution
149	149	treatment program" means a person, private physician, or
150	150	organization that admin isters or dispenses an opioid drug to a
151	151	narcotic addict for the purposes of detoxification or maintenance
152	152	treatment or provides, when necessary and appropriate, comprehensive
153	153	medical and rehabilitation serv ices. A private physician who
154	154	administers buprenorphine with a waiver from the Drug Enforcement
155	155	Administration shall not be considered an opioid substitution
156	156	treatment program. An o pioid substitution treatment program shall
157	157	be certified by the Board of M ental Health and Substance Abuse
158	158	Services, or the Commissioner of Mental Health and Substance Abuse
159	159	Services upon delegation by the Board, and registered with the
160	160	federal Drug Enforce ment Administration for the use of an opioid
161	161	drug to treat narcotic addic tion.
162	162
163	163
164	164	Req. No. 2393 Page 3 1
165	165	2
166	166	3
167	167	4
168	168	5
169	169	6
170	170	7
171	171	8
172	172	9
173	173	10
174	174	11
175	175	12
176	176	13
177	177	14
178	178	15
179	179	16
180	180	17
181	181	18
182	182	19
183	183	20
184	184	21
185	185	22
186	186	23
187	187	24
188	188	1
189	189	2
190	190	3
191	191	4
192	192	5
193	193	6
194	194	7
195	195	8
196	196	9
197	197	10
198	198	11
199	199	12
200	200	13
201	201	14
202	202	15
203	203	16
204	204	17
205	205	18
206	206	19
207	207	20
208	208	21
209	209	22
210	210	23
211	211	24
212	212
213	213	D. The Board of Mental Health and Substance Abuse Services
214	214	shall promulgate rules and standards for the certification of all
215	215	programs, private facilities, and organizations whi ch provide opioid
216	216	substitution treatment directed to those physiologicall y dependent
217	217	on or addicted to opioids. These faci lities and organizations shall
218	218	be known as "Opioid Substitution Treatment Programs " "opioid
219	219	substitution treatment program s". Only certified facilities may
220	220	receive and assist opioid-dependent and addicted persons by
221	221	providing Class II controlled substanc es in opioid substitution
222	222	treatment and rehabilitation.
223	223	E. The Board of Mental Health and Substance Abuse Services
224	224	shall promulgate rules and standards regulating the treatme nt and
225	225	services provided by opio id substitution treatment programs.
226	226	Failure to comply with rules and standards promulgated by the Board
227	227	shall be grounds for revocation, suspension or nonrenewal of
228	228	certification.
229	229	F. Opioid substitution treatment programs shall notify the
230	230	Department of Mental Health and Substance Abuse Services of plan s to
231	231	close or relocate within a minimum of thirty (30) days prior to
232	232	closure or relocation.
233	233	G. Failure to comply with rules and standards promulgated by
234	234	the Board of Mental H ealth and Substance Abuse Servic es pursuant to
235	235	this section shall be grounds for reprimand, suspension, revocation
236	236	or nonrenewal of certification.
237	237
238	238
239	239	Req. No. 2393 Page 4 1
240	240	2
241	241	3
242	242	4
243	243	5
244	244	6
245	245	7
246	246	8
247	247	9
248	248	10
249	249	11
250	250	12
251	251	13
252	252	14
253	253	15
254	254	16
255	255	17
256	256	18
257	257	19
258	258	20
259	259	21
260	260	22
261	261	23
262	262	24
263	263	1
264	264	2
265	265	3
266	266	4
267	267	5
268	268	6
269	269	7
270	270	8
271	271	9
272	272	10
273	273	11
274	274	12
275	275	13
276	276	14
277	277	15
278	278	16
279	279	17
280	280	18
281	281	19
282	282	20
283	283	21
284	284	22
285	285	23
286	286	24
287	287
288	288	H. An opioid substitution treatment program or any other
289	289	healthcare provider or healthcare facility shall not sell or
290	290	dispense methadone to any consumer for unsupervised us e. The opioid
291	291	substitution treatment pro gram or other provider or facility may
292	292	only administer or dispense meth adone to a consumer for onsite
293	293	consumption.
294	294	SECTION 2. This act shall become effective November 1, 2022.
295	295
296	296	58-2-2393 DC 1/19/2022 4:18:52 PM

Oklahoma 2022 Regular Session

Oklahoma Senate Bill SB1438 Compare Versions